Search for: "v. Classen Immunotherapies, Inc."
Results 1 - 20
of 62
Sort by Relevance
|
Sort by Date
18 Dec 2019, 9:59 pm
For example, in Classen Immunotherapies, Inc. v. [read post]
25 Nov 2015, 9:59 pm
Noonan -- The question of the extent to which the "safe harbor" against infringement as part of the Hatch-Waxman Act (set forth in 35 U.S.C § 271(e)(1)) extends to activities post-generic drug approval is unresolved, as evidenced by the different conclusions in Classen Immunotherapies, Inc. v. [read post]
20 May 2015, 10:00 pm
On May 13, 2015, the Federal Circuit confirmed in Classen Immunotherapies, Inc. v. [read post]
14 May 2015, 9:59 pm
Earlier this week, the Federal Circuit continued this expansion in Classen Immunotherapies, Inc. v. [read post]
26 Jun 2013, 1:11 pm
The Way Forward from Mayo Collaborative Services is through the Classen Immunotherapies Remand*The reasoning in Mayo Collaborative Services makes no patent law logical sense on numerous grounds, including disregarding an important paragraph in the Supreme Court’s 1981 case of Diamond v. [read post]
25 Jun 2013, 9:52 pm
In Classen Immunotherapies, Inc. v. [read post]
17 Mar 2013, 9:07 am
Related posts:The Way Forward from Mayo Collaborative Services is through the Classen Immunotherapies Remand*The reasoning in Mayo Collaborative Services makes no patent law logical sense on numerous grounds, including disregarding an important paragraph in the Supreme Court’s 1981 case of Diamond v. [read post]
10 Jan 2013, 12:03 pm
Northwest, Inc. v. [read post]
12 Aug 2012, 11:47 am
Ct. 1289 (2012), according to the District Court in Classen Immunotherapies, Inc. v. [read post]
7 Aug 2012, 11:45 pm
Instead, the patentee Momenta made the investment, did the research, and engineered the new method disclosed in the '886 patent.The Chief Judge states [the majority] "ignores the binding precedent of Classen Immunotherapies, Inc. v. [read post]
7 Aug 2012, 7:43 pm
§ 271(e)(1), particularly in light of the Court’s prior decision in Classen Immunotherapies v. [read post]
18 May 2012, 5:45 am
” See Ultramercial, p. 6; Classen Immunotherapies, Inc. v. [read post]
9 May 2012, 4:25 am
The Way Forward from Mayo Collaborative Services is through the Classen Immunotherapies Remand*The reasoning in Mayo Collaborative Services makes no patent law logical sense on numerous grounds, including disregarding an important paragraph in the Supreme Court’s 1981 case of Diamond v. [read post]
30 Mar 2012, 8:30 am
The way forward to patent-eligibility rationality, as well as sanity, is through the remand decision in Classen Immunotherapies, Inc. v. [read post]
28 Mar 2012, 10:54 am
The Way Forward from Mayo Collaborative Services is through the Classen Immunotherapies Remand*The reasoning in Mayo Collaborative Services makes no patent law logical sense on numerous grounds, including disregarding an important paragraph in the Supreme Court’s 1981 case of Diamond v. [read post]
22 Mar 2012, 4:55 am
Cir. 2011); Classen Immunotherapies, Inc. v. [read post]
Review of the Effects of the Leahy-Smith America Invents Act on Third Party Participation Applicants
1 Feb 2012, 9:15 am
James G. [read post]
30 Jan 2012, 3:49 am
In Ultramercial LLC v. [read post]
12 Dec 2011, 9:02 am
For example, in Classen Immunotherapies, Inc. v. [read post]
3 Nov 2011, 12:48 pm
Kappos; (2) inconsistencies in application of the law apparent from the court's recent decisions in Ultramercial, Classen Immunotherapies v. [read post]
